Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation

Toxicology Letters

Volumn 225, Issue 1, 2014, Pages 43-47

  Becker, Jonas Philipp ^a   Weiss, Johanna ^a   Theile, Dirk ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Carboplatin; Cisplatin; In vitro translation; MRNA; Oxaliplatin

Indexed keywords

CARBOPLATIN; CISPLATIN; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; OXALIPLATIN;

ARTICLE; EVALUATION; IN VITRO STUDY; INTERACTIONS WITH RNA; INTERNAL RIBOSOME ENTRY SITE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSLATION;

CARBOPLATIN; CISPLATIN; DDTC; DIETHYLDITHIOCARBAMATE; GFP; GREEN FLUORESCENT PROTEIN; IN VITRO TRANSLATION; INTERNAL RIBOSOME ENTRY SITE; IRES; MRNA; OXALIPLATIN;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; ORGANOPLATINUM COMPOUNDS; PROTEIN BIOSYNTHESIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 84890417737     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.11.015     Document Type: Article

References (22)

1. Albermann N., Schmitz-Winnenthal F.H., Z'graggen K., Volk C., Hoffmann M.M., Haefeli W.E., Weiss J. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem. Pharmacol. 2005, 70:949-958.
2. Arnould S., Hennebelle I., Canal P., Bugat R., Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur. J. Cancer 2003, 39:112-119.
3. Bannister S.J., Sternson L.A., Repta A.J. Urine analysis of platinum species derived from cis-dichlorodiammineplatinum (II) by high-performance liquid chromatography following derivatization with sodium diethyldithiocarbamate. J. Chromatogr. 1979, 173:333-342.
4. Chalfie M., Tu Y., Euskirchen G., Ward W.W., Prasher D.C. Green fluorescent protein as a marker for gene expression. Science 1994, 263:802-805.
5. Chomczynski P., Sacchi N. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat. Protoc. 2006, 1:581-585.
6. Di Francesco A.M., Ruggiero A., Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell. Mol. Life Sci. 2002, 59:1914-1927.
7. Fung-Kee-Fung M., Oliver T., Elit L., Oza A., Hirte H.W., Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr. Oncol. 2007, 14:195-208.
8. Goodisman J., Hagrman D., Tacka K.A., Souid A.K. Analysis of cytotoxicities of platinum compounds. Cancer Chemother. Pharmacol. 2006, 57:257-267.
9. Goodwin R.A., Asmis T.R. Overview of systemic therapy for colorectal cancer. Clin. Colon Rectal Surg. 2009, 22:251-256.
10. Himmelstein K.J., Patton T.F., Belt R.J., Taylor S., Repta A.J., Sternson L.A. Clinical kinetics on intact cisplatin and some related species. Clin. Pharmacol. Ther. 1981, 29:658-664.
11. Hostetter A.A., Osborn M.F., DeRose V.J. RNA-Pt adducts following cisplatin treatment of Saccharomyces cerevisiae. ACS Chem. Biol. 2012, 7:218-225.
12. Hägerlöf M., Papsai P., Chow C.S., Elmroth S.K. More pronounced salt dependence and higher reactivity for platination of the hairpin r(CGCGUUGUUCGCG) compared with d(CGCGTTGTTCGCG). J. Biol. Inorg. Chem. 2006, 11:974-990.
13. Ihnat M.A., Lariviere J.P., Warren A.J., La Ronde N., Blaxall J.R., Pierre K.M., Turpie B.W., Hamilton J.W. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents. Clin. Cancer Res. 1997, 3:1339-1346.
14. Li X., Zhao X., Fang Y., Jiang X., Duong T., Fan C., Huang C.C., Kain S.R. Generation of destabilized green fluorescent protein as a transcription reporter. J. Biol. Chem. 1998, 273:34970-34975.
15. O'Dwyer P.J., Stevenson J.P., Johnson S.W. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000, 59(4):19-27.
16. Papsai P., Snygg A.S., Aldag J., Elmroth S.K. Platination of full length tRNA(Ala) and truncated versions of the acceptor stem and anticodon loop. Dalton Trans. 2008, 38:5225-5234.
17. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 2007, 33:9-23.
18. Rijal K., Chow C.S. A new role for cisplatin: probing ribosomal RNA structure. Chem. Commun. (Camb.) 2009, 107-109.
19. Rosenberg J., Sato P. Messenger RNA loses the ability to direct in vitro peptide synthesis following incubation with cisplatin. Mol. Pharmacol. 1988, 1988:611-616.
20. Sun Y., Yin R., Gou S., Zhaojian Antitumor platinum (II) complexes of N-monoalkyl-1R, 2R-diaminocyclohexane derivatives with alkyl groups as hindrance. J. Inorg. Biochem. 2012, 112:68-76.
21. Tegeder I., Bräutigam L., Seegel M., Al-Dam A., Turowski B., Geisslinger G., Kovács A.F. Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer. Clin. Pharmacol. Ther. 2003, 73:417-426.
22. Woynarowski J.M., Chapman W.G., Napier C., Herzig M.C.S., Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol. Pharmacol. 1998, 54:770-777.